Targeted disruption of PDE3B, but not PDE3A, protects murine heart from ischemia/reperfusion injury

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 17, 2015, Pages E2253-E2262

  Chung, Youn Wook ^a,b   Lagranha, Claudia ^a   Chen, Yong ^a   Sun, Junhui ^a   Tong, Guang ^a,c   Hockman, Steven C ^a   Ahmad, Faiyaz ^a   Esfahani, Shervin G ^a   Bae, Dahae H ^a   Polidovitch, Nazari ^d   Wu, Jian ^d   Rhee, Dong Keun ^a   Lee, Beom Seob ^b,e   Gucek, Marjan ^a   Daniels, Mathew P ^a   Brantner, Christine A ^a   Backx, Peter H ^d,f   Murphy, Elizabeth ^a   Manganiello, Vincent C ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b Yonsei University College of Medicine   (South Korea)

^c GUANGZHOU GENERAL HOSPITAL OF GUANGZHOU MILITARY COMMAND   (China)

^d UNIVERSITY OF TORONTO   (Canada)

^e Yonsei University   (South Korea)

^f UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

Ischemia reperfusion injury; Membrane repair; PDe3B Mice; Protein kinase A; Signalosome

Indexed keywords

CAVEOLIN 3; CILOSTAMIDE; CONNEXIN 43; CYCLIC AMP DEPENDENT PROTEIN KINASE; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; PAXILLINE; PHOSPHODIESTERASE III; PHOSPHODIESTERASE III SUBFAMILY A; PHOSPHODIESTERASE III SUBFAMILY B; PROTEIN BCL 2; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; CARRIER PROTEIN; CAV3 PROTEIN, MOUSE; CYCLIC AMP; PDE3A PROTEIN, MOUSE; PDE3B PROTEIN, MOUSE; PHOSPHODIESTERASE INHIBITOR; QUINOLONE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENZYME LOCALIZATION; GENE DELETION; HEART FUNCTION; HEART INFARCTION SIZE; HEART MITOCHONDRION; HEART PROTECTION; IN VITRO STUDY; IN VIVO STUDY; ISCHEMIC PRECONDITIONING; MITOCHONDRION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEOMICS; REPERFUSION INJURY; SIGNAL TRANSDUCTION; TRANSVERSE TUBULAR SYSTEM; WILD TYPE; ANIMAL; DEFICIENCY; ENZYMOLOGY; GENETICS; HEART MUSCLE; KNOCKOUT MOUSE; METABOLISM; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; PATHOLOGY;

MURINAE; MUS; RODENTIA;

ANIMALS; CAVEOLIN 3; CONNEXIN 43; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 3; MICE; MICE, KNOCKOUT; MITOCHONDRIA, HEART; MITOCHONDRIAL MEMBRANE TRANSPORT PROTEINS; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; PHOSPHODIESTERASE INHIBITORS; QUINOLONES;

EID: 84928558139     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1416230112     Document Type: Article

References (73)

1. Zaccolo M, Movsesian MA (2007) cAMP and cGMP signaling cross-talk: Role of phosphodiesterases and implications for cardiac pathophysiology. Circ Res 100(11):1569-1578.
2. Shakur Y, et al. (2001) Regulation and function of the cyclic nucleotide phosphodiesterase (PDE3) gene family. Prog Nucleic Acid Res Mol Biol 66:241-277.
3. Masciarelli S, et al. (2004) Cyclic nucleotide phosphodiesterase 3A-deficient mice as a model of female infertility. J Clin Invest 114(2):196-205.
4. Choi YH, et al. (2006) Alterations in regulation of energy homeostasis in cyclic nucleotide phosphodiesterase 3B-null mice. J Clin Invest 116(12):3240-3251.
5. Shakur Y, et al. (2002) Comparison of the effects of cilostazol and milrinone on cAMP-PDE activity, intracellular cAMP and calcium in the heart. Cardiovasc Drugs Ther 16(5):417-427.
6. Sanada S, et al. (2001) Cardioprotective effect afforded by transient exposure to phosphodiesterase III inhibitors: The role of protein kinase A and p38 mitogen-activated protein kinase. Circulation 104(6):705-710.
7. Manickavasagam S, et al. (2007) The cardioprotective effect of a statin and cilostazol combination: Relationship to Akt and endothelial nitric oxide synthase activation. Cardiovasc Drugs Ther 21(5):321-330.
8. Fukasawa M, Nishida H, Sato T, Miyazaki M, Nakaya H (2008) 6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2-(1H)quinolinone (cilostazol), a phosphodiesterase type 3 inhibitor, reduces infarct size via activation of mitochondrial Ca2+-activated K+ channels in rabbit hearts. J Pharmacol Exp Ther 326(1):100-104.
9. Tosaka S, et al. (2007) Cardioprotection induced by olprinone, a phosphodiesterase III inhibitor, involves phosphatidylinositol-3-OH kinase-Akt and a mitochondrial permeability transition pore during early reperfusion. J Anesth 21(2):176-180.
10. Ockaili R, Salloum F, Hawkins J, Kukreja RC (2002) Sildenafil (Viagra) induces powerful cardioprotective effect via opening of mitochondrial K(ATP) channels in rabbits. Am J Physiol Heart Circ Physiol 283(3):H1263-H1269.
11. WangX, Fisher PW, Xi L, KukrejaRC (2008) Essential role of mitochondrial Ca2+-activated and ATP-sensitive K+ channels in sildenafil-induced late cardioprotection. J Mol Cell Cardiol 44(1):105-113.
12. Xu W, et al. (2002) Cytoprotective role of Ca2+-activated K+ channels in the cardiac inner mitochondrial membrane. Science 298(5595):1029-1033.
13. Sato T, Saito T, Saegusa N, Nakaya H (2005) Mitochondrial Ca2+-activated K+ channels in cardiac myocytes: A mechanism of the cardioprotective effect and modulation by protein kinase A. Circulation 111(2):198-203.
14. O' Rourke B (2007) Mitochondrial ion channels. Annu Rev Physiol 69:19-49.
15. Murry CE, Jennings RB, Reimer KA (1986) Preconditioning with ischemia: A delay of lethal cell injury in ischemic myocardium. Circulation 74(5):1124-1136.
16. Murphy E, Steenbergen C (2008) Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiol Rev 88(2):581-609.
17. Quinlan CL, et al. (2008) Conditioning the heart induces formation of signalosomes that interact with mitochondria to open mitoKATP channels. Am J Physiol Heart Circ Physiol 295(3):H953-H961.
18. Insel PA, Patel HH (2009) Membrane rafts and caveolae in cardiovascular signaling. Curr Opin Nephrol Hypertens 18(1):50-56.
19. Fischmeister R, et al. (2006) Compartmentation of cyclic nucleotide signaling in the heart: The role of cyclic nucleotide phosphodiesterases. Circ Res 99(8):816-828.
20. Willoughby D, Cooper DM (2007) Organization and Ca2+ regulation of adenylyl cyclases in cAMP microdomains. Physiol Rev 87(3):965-1010.
21. Maurice DH, et al. (2014) Advances in targeting cyclic nucleotide phosphodiesterases. Nat Rev Drug Discov 13(4):290-314.
22. Juhaszova M, et al. (2009) Role of glycogen synthase kinase-3beta in cardioprotection. Circ Res 104(11):1240-1252.
23. Hayashi T, Rizzuto R, Hajnoczky G, Su TP (2009) MAM: More than just a housekeeper. Trends Cell Biol 19(2):81-88.
24. Ruiz-Meana M, Fernandez-Sanz C, Garcia-Dorado D (2010) The SR-mitochondria interaction: A new player in cardiac pathophysiology. Cardiovasc Res 88(1):30-39.
25. Odagiri K, et al. (2009) Local control of mitochondrial membrane potential, permeability transition pore and reactive oxygen species by calcium and calmodulin in rat ventricular myocytes. J Mol Cell Cardiol 46(6):989-997.
26. Ziman AP, Gómez-Viquez NL, Bloch RJ, Lederer WJ (2010) Excitation-contraction coupling changes during postnatal cardiac development. J Mol Cell Cardiol 48(2):379-386.
27. Beca S, et al. (2013) Phosphodiesterase type 3A regulates basal myocardial contractility through interacting with sarcoplasmic reticulum calcium ATPase type 2a signaling complexes in mouse heart. Circ Res 112(2):289-297.
28. Tsutsumi YM, et al. (2008) Cardiac-specific overexpression of caveolin-3 induces endogenous cardiac protection by mimicking ischemic preconditioning. Circulation 118(19):1979-1988.
29. Fridolfsson HN, et al. (2012) Mitochondria-localized caveolin in adaptation to cellular stress and injury. FASEB J 26(11):4637-4649.
30. Hagiwara Y, et al. (2000) Caveolin-3 deficiency causes muscle degeneration in mice. Hum Mol Genet 9(20):3047-3054.
31. Horikawa YT, et al. (2008) Caveolin-3 expression and caveolae are required for iso-flurane- induced cardiac protection from hypoxia and ischemia/reperfusion injury. J Mol Cell Cardiol 44(1):123-130.
32. Juhaszova M, et al. (2004) Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J Clin Invest 113(11):1535-1549.
33. Yan C, Miller CL, Abe J (2007) Regulation of phosphodiesterase 3 and inducible cAMP early repressor in the heart. Circ Res 100(4):489-501.
34. Boengler K, et al. (2009) Presence of connexin 43 in subsarcolemmal, but not in interfibrillar cardiomyocyte mitochondria. Basic Res Cardiol 104(2):141-147.
35. Boengler K, et al. (2005) Connexin 43 in cardiomyocyte mitochondria and its increase by ischemic preconditioning. Cardiovasc Res 67(2):234-244.
36. Rodriguez-Sinovas A, et al. (2006) Translocation of connexin 43 to the inner mitochondrial membrane of cardiomyocytes through the heat shock protein 90-dependent TOM pathway and its importance for cardioprotection. Circ Res 99(1):93-101.
37. Palmer JW, Tandler B, Hoppel CL (1986) Heterogeneous response of subsarcolemmal heart mitochondria to calcium. Am J Physiol 250(5 Pt 2):H741-H748.
38. Schroeder F, et al. (1991) Membrane cholesterol dynamics: Cholesterol domains and kinetic pools. Proc Soc Exp Biol Med 196(3):235-252.
39. Patel HH, Murray F, Insel PA (2008) Caveolae as organizers of pharmacologically relevant signal transduction molecules. Annu Rev Pharmacol Toxicol 48:359-391.
40. Han R, Campbell KP (2007) Dysferlin and muscle membrane repair. Curr Opin Cell Biol 19(4):409-416.
41. Cai C, et al. (2009) Membrane repair defects in muscular dystrophy are linked to altered interaction between MG53, caveolin-3, and dysferlin. J Biol Chem 284(23):15894-15902.
42. Nguyen T, et al. (2012) Acute inhibition of GSK causes mitochondrial remodeling. Am J Physiol Heart Circ Physiol 302(11):H2439-H2445.
43. Sun B, et al. (2007) Role of phosphodiesterase type 3A and 3B in regulating platelet and cardiac function using subtype-selective knockout mice. Cell Signal 19(8):1765-1771.
44. Begum N, Hockman S, Manganiello VC (2011) Phosphodiesterase 3A (PDE3A) deletion suppresses proliferation of cultured murine vascular smooth muscle cells (VSMCs) via inhibition of mitogen-activated protein kinase (MAPK) signaling and alterations in critical cell cycle regulatory proteins. J Biol Chem 286(29):26238-26249.
45. Zhang Z, et al. (2006) Reduced 6-month resource use and costs associated with cilostazol in patients after successful coronary stent implantation: Results from the Cilostazol for RESTenosis (CREST) trial. Am Heart J 152(4):770-776.
46. Katakami N, Kim YS, Kawamori R, Yamasaki Y (2010) The phosphodiesterase inhibitor cilostazol induces regression of carotid atherosclerosis in subjects with type 2 diabetes mellitus: Principal results of the Diabetic Atherosclerosis Prevention by Cilostazol (DAPC) study: A randomized trial. Circulation 121(23):2584-2591.
47. Guirguis E, et al. (2013) A role for phosphodiesterase 3B in acquisition of brown fat characteristics by white adipose tissue in male mice. Endocrinology 154(9):3152-3167.
48. Steinberg SF, Brunton LL (2001) Compartmentation of G protein-coupled signaling pathways in cardiac myocytes. Annu Rev Pharmacol Toxicol 41:751-773.
49. Michel JJ, Scott JD (2002) AKAP mediated signal transduction. Annu Rev Pharmacol Toxicol 42:235-257.
50. Kerfant BG, et al. (2007) PI3Kgamma is required for PDE4, not PDE3, activity in subcellular microdomains containing the sarcoplasmic reticular calcium ATPase in cardiomyocytes. Circ Res 101(4):400-408.
51. Ghigo A, et al. (2012) Phosphoinositide 3-kinase γ protects against catecholamine-induced ventricular arrhythmia through protein kinase A-mediated regulation of distinct phosphodiesterases. Circulation 126(17):2073-2083.
52. Tong H, Imahashi K, Steenbergen C, Murphy E (2002) Phosphorylation of glycogen synthase kinase-3beta during preconditioning through a phosphatidylinositol-3-kinase - dependent pathway is cardioprotective. Circ Res 90(4):377-379.
53. Das A, Xi L, Kukreja RC (2008) Protein kinase G-dependent cardioprotective mechanism of phosphodiesterase-5 inhibition involves phosphorylation of ERK and GSK3beta. J Biol Chem 283(43):29572-29585.
54. Young JC, Hoogenraad NJ, Hartl FU (2003) Molecular chaperones Hsp90 and Hsp70 deliver preproteins to the mitochondrial import receptor Tom70. Cell 112(1):41-50.
55. Ishikawa S, et al. (2012) Role of connexin-43 in protective PI3K-Akt-GSK-3β signaling in cardiomyocytes. Am J Physiol Heart Circ Physiol 302(12):H2536-H2544.
56. Cao CM, et al. (2010) MG53 constitutes a primary determinant of cardiac ischemic preconditioning. Circulation 121(23):2565-2574.
57. Wang X, et al. (2010) Cardioprotection of ischemia/reperfusion injury by cholesterol-dependent MG53-mediated membrane repair. Circ Res 107(1):76-83.
58. Song KS, et al. (1996) Expression of caveolin-3 in skeletal, cardiac, and smooth muscle cells. Caveolin-3 is a component of the sarcolemma and co-fractionates with dystrophin and dystrophin-associated glycoproteins. J Biol Chem 271(25):15160-15165.
59. Parton RG, Way M, Zorzi N, Stang E (1997) Caveolin-3 associates with developing T-tubules during muscle differentiation. J Cell Biol 136(1):137-154.
60. Ahmad F, et al. (2015) Regulation of SERCA2 activity by PDE3A in human myocardium: Phosphorylation-dependent interaction of PDE3A1 with SERCA2. J Biol Chem 290(11):6763-6776.
61. Ahmad F, et al. (2007) Insulin-induced formation of macromolecular complexes involved in activation of cyclic nucleotide phosphodiesterase 3B (PDE3B) and its interaction with PKB. Biochem J 404(2):257-268.
62. Ahmad F, et al. (2009) Differential regulation of adipocyte PDE3B in distinct membrane compartments by insulin and the beta3-adrenergic receptor agonist CL316243: Effects of caveolin-1 knockdown on formation/maintenance of macromolecular signalling complexes. Biochem J 424(3):399-410.
63. Perino A, Ghigo A, Scott JD, Hirsch E (2012) Anchoring proteins as regulators of signaling pathways. Circ Res 111(4):482-492.
64. Perino A, et al. (2011) Integrating cardiac PIP3 and cAMP signaling through a PKA anchoring function of p110γ. Mol Cell 42(1):84-95.
65. Patrucco E, et al. (2004) PI3Kgamma modulates the cardiac response to chronic pressure overload by distinct kinase-dependent and -independent effects. Cell 118(3):375-387.
66. Perrino C, Rockman HA, Chiariello M (2006) Targeted inhibition of phosphoinositide 3-kinase activity as a novel strategy to normalize beta-adrenergic receptor function in heart failure. Vascul Pharmacol 45(2):77-85.
67. Mangiafico RA, Fiore CE (2009) Current management of intermittent claudication: The role of pharmacological and nonpharmacological symptom-directed therapies. Curr Vasc Pharmacol 7(3):394-413.
68. Packer M, et al.; The PROMISE Study Research Group (1991) Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 325(21):1468-1475.
69. Oikawa M, et al. (2013) Cyclic nucleotide phosphodiesterase 3A1 protects the heart against ischemia-reperfusion injury. J Mol Cell Cardiol 64:11-19.
70. Ye Y, et al. (2013) Phosphodiesterase-3 inhibition augments the myocardial infarct size-limiting effects of exenatide in mice with type 2 diabetes. Am J Physiol Heart Circ Physiol 304(1):H131-H141.
71. Birnbaum Y, et al. (2012) Phosphodiesterase III inhibition increases cAMP levels and augments the infarct size limiting effect of a DPP-4 inhibitor in mice with type-2 diabetes mellitus. Cardiovasc Drugs Ther 26(6):445-456.
72. Wechsler J, et al. (2002) Isoforms of cyclic nucleotide phosphodiesterase PDE3A in cardiac myocytes. J Biol Chem 277(41):38072-38078.
73. Hambleton R, et al. (2005) Isoforms of cyclic nucleotide phosphodiesterase PDE3 and their contribution to cAMP hydrolytic activity in subcellular fractions of human myocardium. J Biol Chem 280(47):39168-39174.